Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Sells $21,640.00 in Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $10.82, for a total transaction of $21,640.00. Following the completion of the transaction, the president now owns 2,936,467 shares in the company, valued at approximately $31,772,572.94. The trade was a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Songjiang Ma also recently made the following trade(s):

• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $11.05, for a total transaction of $22,100.00.

Gyre Therapeutics Stock Performance

GYRE stock opened at $11.90 on Thursday. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $30.39. The company’s fifty day simple moving average is $12.76 and its 200 day simple moving average is $12.62.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. FMR LLC bought a new stake in Gyre Therapeutics in the third quarter valued at $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% in the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after purchasing an additional 6,855 shares in the last quarter. State Street Corp increased its stake in Gyre Therapeutics by 8.8% in the third quarter. State Street Corp now owns 104,490 shares of the company’s stock valued at $1,310,000 after purchasing an additional 8,412 shares in the last quarter. Rhumbline Advisers bought a new stake in Gyre Therapeutics in the second quarter valued at $123,000. Finally, Renaissance Technologies LLC bought a new stake in Gyre Therapeutics in the second quarter valued at $166,000. 23.99% of the stock is owned by institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.